Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
08 October 2021 - 12:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a
clinical-stage global developer of cell-based technologies and
therapeutics, today announced co-development of a novel, cell-free,
in-silico system to facilitate the Company’s drug development
efforts, together with the Institute for Synthetic Bioarchitectures
at the University of Natural Resources and Life Sciences (BOKU) in
Vienna, Austria. A study of the new technology was featured in the
September 2021 issue of Membranes, an international, peer-reviewed
journal.
The new technology reveals that difficult-to-study cell membrane
proteins can be efficiently expressed in a cell-free system,
allowing for their evaluation as potentially druggable targets. The
technology expands Avalon’s ability to design and produce novel
membrane proteins—including receptors found on the surface of
immune cells and cancer cells that are important for cell signaling
and diseases such as cancer—providing Avalon an efficient tool to
screen and optimize potential therapeutic targets.
Proteins function within cells and are also present on cell
surfaces, embedded within the cell’s outer membrane. These membrane
proteins include cell surface receptors that function in cell
signaling and regulation of communication with other cells and
tissues. These molecules are important drug targets and include
receptors on immune cells such as T-cells for the development of
cellular immunotherapies.
The researchers used computer-based models, developed at the
University of Vienna, to identify factors that optimize the
expression of membrane proteins in a cell-free, in-silico system,
resulting in high protein yield. The study demonstrated the success
of this method by showing the ability to manipulate and express a
drug target membrane protein, a human voltage-dependent anion
channel, at high yield.
The use of this novel technology can improve knowledge about
receptors and other membrane proteins to better understand the
biology of drug targets and to develop novel therapies, including
immunotherapies for cancer.
“With this innovative in-silico approach co-developed with
Avalon, we achieved a breakthrough in the design and optimization
of the structure-function of membrane receptors to enhance our
development of novel drug and cell-based therapeutics,” said
Professor Eva-Kathrin Ehmoser, Director of the Institute for
Synthetic Bioarchitectures, Department of BioNanoSciences, BOKU, a
lead author of the study.
“Our partnership with BOKU researchers is yielding novel tools
and discoveries that allow us to identify drug targets that have
been traditionally out of reach due to the inability of existing
technology to synthesize membrane proteins in a laboratory,” said
David Jin, M.D., Ph.D., President and Chief Executive Officer of
Avalon. “This approach will expand our capabilities and repertoire
in designing novel targets for immuno-oncology and cellular
medicine,” added Dr. Jin.
The new technology is a direct result of a collaboration between
the Company and researchers at BOKU, Vienna, the University of
Vienna, the Science for Life Laboratory within the Division of
Nanobiotechnology at the KTH Royal Institute of Technology in
Stockholm, Sweden and the Department of Biochemistry at the King
Abdulaziz University in Jeddah, Saudi Arabia.
About Avalon GloboCare Corp.Avalon GloboCare
Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated,
leading CellTech bio-developer dedicated to advancing and
empowering innovative, transformative immune effector cell therapy,
exosome technology, as well as COVID-19 related diagnostics and
therapeutics. Avalon also provides strategic advisory and
outsourcing services to facilitate and enhance its clients' growth
and development, as well as competitiveness in healthcare and
CellTech industry markets. Through its subsidiary structure with
unique integration of verticals from innovative R&D to
automated bioproduction and accelerated clinical development,
Avalon is establishing a leading role in the fields of cellular
immunotherapy (including CAR-T/NK), exosome technology (ACTEX™),
and regenerative therapeutics. For more information about Avalon
GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments,
please follow our twitter at @avalongc_avco
Forward-Looking StatementsCertain statements
contained in this press release may constitute "forward-looking
statements." Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website
(http://www.sec.gov). In addition to these factors, actual future
performance, outcomes, and results may differ materially because of
more general factors including (without limitation) general
industry and market conditions and growth rates, economic
conditions, and governmental and public policy changes. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact Information: Avalon GloboCare
Corp.4400 Route 9, Suite 3100Freehold, NJ
07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications,
LLCTel: (212) 671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Mar 2023 to Mar 2024